The product Arimidex, manufactured by Prime Pharma, was submitted for independent analysis by panda0435. The sample was analyzed by Janoshik Analytical, and the results indicated a measured concentration of 0.99 mg per tablet, which is slightly below the labeled claim of 1 mg, representing 99% of the label specification.
Testing was initiated on 20 January 2025, with the sample received on 21 January 2025, and analysis completed on 24 January 2025. While the results show a minor discrepancy from the labeled dose, they reflect a product consistent with its batch. This report aims to provide transparency and support harm reduction efforts by helping consumers make informed decisions about their use of pharmaceutical products.
Detailed Report
Product Overview
- Manufacturer: Prime Pharma
- Product Name: Arimidex
- Active Ingredient: Anastrozole
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #56339
- Testing Ordered: 20 January 2025
- Sample Received: 21 January 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: panda0435 (Individual)
- Analysis Paid For By: panda0435 (Individual)
Testing Results
| Specification | Measured Concentration | Accuracy | Variance |
|---|---|---|---|
| 1 mg (as stated) | 0.99 mg | 99% | -1% |
Verification Details
- Verification URL: https://janoshik.com/tests/56339_P7KWML55CHP6
Evaluation of Individual-Submitted Testing
The analysis confirms that the tested sample of Arimidex contains 0.99 mg per tablet, which is slightly below the labeled concentration of 1 mg (by -1%). The minor discrepancy observed here falls within acceptable tolerance ranges for pharmaceutical products. It’s important to note that the sample was submitted by panda0435, an individual consumer with no commercial interests, and not by a reseller, distributor, or manufacturer. This eliminates any potential bias or commercial conflict of interest. However, to fully ensure product consistency, independent third-party testing across multiple batches is recommended.
Conclusion
The analysis of Arimidex confirms that the product contains 0.99 mg per tablet, which is slightly under the labeled dose of 1 mg. The result is consistent with manufacturing standards and falls within acceptable pharmaceutical ranges. To verify the results, consumers can use the provided unique key. Regular testing is encouraged to ensure consistency and quality across all batches.
This report is designed to educate consumers and promote harm reduction by encouraging informed decision-making when using pharmaceutical products.
Disclaimer
This report is for educational and harm reduction purposes. The results pertain only to the tested batch and may not reflect the quality of other batches. Although panda0435 is an individual consumer with no known commercial interests, it is always important to evaluate testing data alongside third-party or independent results for a comprehensive understanding. Readers are advised to consult healthcare professionals and adhere to local regulations before using such products.
